STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #994 by analyst upside · 2026-06-27
AORT
Artivion, Inc.
Healthcare · Market Cap $1B · P/E 94.4x
ANALYST PRICE TARGET
+77.9%
implied upside to consensus target
Current Price $23.61
Consensus Target $42.0
Bull Target $48.0
Bear Target $36.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
5
Hold
1
Sell
0
52-Week Low $19.16
52-Week High $48.25
YTD Return -46.9%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 94.4x
Forward P/E 32.8x
EPS (TTM) $0.25
PEG Ratio 643.75
Dividend Yield N/A
Revenue (TTM) $459M
Profit Margin 2.5%
52-WEEK RANGE
52-Week Low $19.16
52-Week High $48.25
Current Price $23.61
Bear Target $36.0
Bull Target $48.0
● Now $23.61 ● Target $42.0
TRADING DATA
Avg Volume 707K
YTD Return -46.9%
Analyst Count 8
Consensus Buy
Upside to Target +77.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Artivion, Inc. (AORT) is currently trading at $23.61 with a Wall Street consensus price target of $42.0, implying potential upside of 77.9% over the next 12 months. 8 analysts currently cover AORT, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $48.0, while the most cautious has a target of $36.0.

AORT operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 46.9% year-to-date and is currently trading near the lower end of its 52-week range of $19.16 – $48.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for AORT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-06-16 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
Needham — Reiterated
Buy → Buy 2026-05-08 20% win rate (5 calls)
Ladenburg Thalmann ↑ Upgrade
Neutral → Buy 2026-04-10 25% win rate (8 calls)
Needham reit
Buy → Buy 2026-04-07 20% win rate (5 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2026-02-13 Building track record
Needham reit
Buy → Buy 2026-02-02 20% win rate (5 calls)
Canaccord Genuity — Reiterated
Buy → Buy 2025-11-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
17/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →